Business
Moleculin Reports Third Quarter 2021 Financial Results and Provides Programs Update
- Up to six clinical trials expected to be underway or with regulatory clearance by the end of 2021 - - Preliminary clinical activity for Annamycin seen in
About this update from Moleculin Biotech, Inc.
[{"type":"text","content":"- Up to six clinical trials expected to be underway or with regulatory clearance by the end of 2021 -\n - Preliminary clinical activity for Annamycin seen in interim results from its US Phase 1b/2 clinical trial for the treatment of soft tissue sarcoma (STS) lung metastases -\n - STS lung metastases trial continues to recruit rapidly -\n - Received favorable opinion from the MHRA to commence first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 in healthy volunteers for the treatment of COVID-19, expected to commence in Q4 2021 -\n - Additional key clinical and regulatory milestones expected throughout the next 18 months -\n\n\nHOUSTON, Nov. 11, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin, we or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported its financial results for the quarter ended September 30, 2021. The Company also provided an update on its portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.\n\n \n \n \n \n \n \n\n \n\"With up to six clinical trials that are either currently underway or expected to have regulatory clearance by the end of 2021, we have made tremendous fundamental progress, and this is truly an exciting time at Moleculin. Furthermore, we believe at least one additional trial will be approved in early 2022. We continue to be encouraged by both the demonstrated potential and data seen across our portfolio of drug candidates,\" commented Walter Klemp, Chairman and CEO of Moleculin.\nHe continued, \"We are extremely pleased that the STS lung metastases trial recently expanded to a total of three sites and that we are now in the third cohort with the first patient already treated and the final two patients in screening. This trial continues to recruit rapidly, and, on this pace, we could see the Phase 2 begin in the first half of 2022.\"\nConcluding, he added, \"The unmet medical needs that people with highly resistant tumors and viruses are faced with continue to be a driving force as we work to develop safe and effective treatments in a number of oncology and viral indications. We are dedicated to advancing our three core technologies and, I believe, are well-positioned to achieve the key value drivers we ...